Moreover, future studies involving TACE application in animal models with primary HCC [42] may contribute to expediting the clinical implementation of targeting the involved CEBPA-ACSL4-lipid catabolism pathway in HCC treatment. This evidence concerns the gene ACSL4 and hepatocellular carcinoma.